Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:IBRX NASDAQ:IMNM NYSE:QGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$96.55-4.3%$116.01$5.69▼$148.83$8.04B0.692.86 million shs1.16 million shsIBRXImmunityBio$7.10-1.4%$7.55$1.95▼$12.43$7.54B0.0313.86 million shs8.79 million shsIMNMImmunome$18.38+0.1%$21.77$7.96▼$27.65$2.08B2.041.24 million shs2.07 million shsQGENQiagen$37.07-0.9%$37.07$32.53▼$57.81$7.71B0.662.05 million shs1.89 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+2.90%-3.87%-16.90%-12.67%+1,259.43%IBRXImmunityBio+3.15%-1.23%-11.33%-14.18%+122.22%IMNMImmunome+1.10%-6.71%-19.08%-9.82%+93.47%QGENQiagen+0.95%-0.33%+11.04%-7.91%-23.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$96.55-4.3%$116.01$5.69▼$148.83$8.04B0.692.86 million shs1.16 million shsIBRXImmunityBio$7.10-1.4%$7.55$1.95▼$12.43$7.54B0.0313.86 million shs8.79 million shsIMNMImmunome$18.38+0.1%$21.77$7.96▼$27.65$2.08B2.041.24 million shs2.07 million shsQGENQiagen$37.07-0.9%$37.07$32.53▼$57.81$7.71B0.662.05 million shs1.89 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+2.90%-3.87%-16.90%-12.67%+1,259.43%IBRXImmunityBio+3.15%-1.23%-11.33%-14.18%+122.22%IMNMImmunome+1.10%-6.71%-19.08%-9.82%+93.47%QGENQiagen+0.95%-0.33%+11.04%-7.91%-23.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.73Moderate Buy$130.0834.72% UpsideIBRXImmunityBio 2.71Moderate Buy$14.20100.00% UpsideIMNMImmunome 2.85Moderate Buy$33.1780.45% UpsideQGENQiagen 2.42Hold$44.9821.34% UpsideCurrent Analyst Ratings BreakdownLatest IMNM, ABVX, QGEN, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026IMNMImmunome WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$31.006/3/2026ABVXAbivax Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$136.006/3/2026ABVXAbivax Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/2/2026ABVXAbivax Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$140.00 ➝ $135.006/2/2026ABVXAbivax Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$145.00 ➝ $132.006/2/2026ABVXAbivax CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/2/2026ABVXAbivax Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$160.00 ➝ $90.006/2/2026ABVXAbivax Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$131.00 ➝ $187.006/2/2026ABVXAbivax WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Neutral$110.00 ➝ $90.006/2/2026ABVXAbivax BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$150.006/2/2026IBRXImmunityBio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/AIBRXImmunityBio$113.29M65.64N/AN/A($0.51) per share-13.92IMNMImmunome$6.94M299.93N/AN/A$5.75 per share3.20QGENQiagen$2.09B3.65$3.37 per share10.99$17.89 per share2.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%N/AIBRXImmunityBio-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%8/4/2026 (Estimated)IMNMImmunome-$212.39M-$2.38N/AN/AN/AN/A-51.15%-47.32%8/5/2026 (Estimated)QGENQiagen$424.88M$1.9115.3814.043.7219.16%14.40%8.40%8/4/2026 (Estimated)Latest IMNM, ABVX, QGEN, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2026Q1 2026ABVXAbivax-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million5/12/2026Q1 2026IMNMImmunome-$0.60-$0.48+$0.12-$0.48$0.22 millionN/A5/7/2026Q1 2026IBRXImmunityBio-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million5/7/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$496.15 million$492.32 million3/23/2026Q4 2025ABVXAbivax-$2.24-$1.20+$1.04-$1.20$1.80 million$0.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/AQGENQiagen$0.260.70%N/A13.61%N/ALatest IMNM, ABVX, QGEN, and IBRX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/11/2026QGENQiagenannual$0.351.04%7/7/20267/7/20267/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A8.258.25IBRXImmunityBioN/A6.676.66IMNMImmunomeN/A21.6821.68QGENQiagen0.493.212.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%IBRXImmunityBio8.58%IMNMImmunome44.58%QGENQiagen70.00%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AIBRXImmunityBio69.48%IMNMImmunome7.21%QGENQiagen9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6179.69 millionN/ANot OptionableIBRXImmunityBio5901.05 billion319.65 millionOptionableIMNMImmunome40113.25 million105.09 millionOptionableQGENQiagen5,654206.07 million187.53 millionOptionableIMNM, ABVX, QGEN, and IBRX HeadlinesRecent News About These CompaniesA Look at Qiagen NV (QGEN) After 4.2% Gain -- GF Value $52.66 vs Price $37.75June 9 at 9:02 PM | gurufocus.comQiagen (QGEN) Up 12.1% Since Last Earnings Report: Can It Continue?June 5, 2026 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENJune 4, 2026 | prnewswire.comQiagen N.V. (QGEN) Presents at Jefferies Global Healthcare Conference 2026 TranscriptJune 3, 2026 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENJune 2, 2026 | globenewswire.comEvaluating Qiagen (QGEN) Valuation After Recent Short Term Share Price RecoveryJune 2, 2026 | finance.yahoo.comQiagen N.V. (QGEN) Presents at Deutsche Bank German Corporate Conference - SlideshowJune 1, 2026 | seekingalpha.comLegal & General Group Plc Sells 40,221 Shares of Qiagen N.V. $QGENMay 30, 2026 | marketbeat.comIs QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?May 29, 2026 | zacks.comQIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus OutbreakMay 28, 2026 | businesswire.comQIAGEN Business Breakdown and Growth Drivers for 2026May 28, 2026 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 28, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 26, 2026 | globenewswire.comQGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.May 21, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 21, 2026 | prnewswire.comQIAGEN Stock Up on the Launch of AI-Powered Workflow Agent PlatformMay 21, 2026 | zacks.comQIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflowsMay 20, 2026 | businesswire.com3 Stocks in Focus That Recently Declared Dividend Hikes Amid High InflationMay 20, 2026 | zacks.comQiagen (QGEN) Securities Fraud Investigation - Levi & KorsinskyMay 20, 2026 | prnewswire.comQGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.May 19, 2026 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 19, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMNM, ABVX, QGEN, and IBRX Company DescriptionsAbivax NASDAQ:ABVX$96.55 -4.32 (-4.28%) Closing price 04:00 PM EasternExtended Trading$98.22 +1.67 (+1.73%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.ImmunityBio NASDAQ:IBRX$7.10 -0.10 (-1.39%) Closing price 04:00 PM EasternExtended Trading$7.10 +0.01 (+0.07%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Immunome NASDAQ:IMNM$18.38 +0.02 (+0.11%) Closing price 04:00 PM EasternExtended Trading$18.38 0.00 (0.00%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Qiagen NYSE:QGEN$37.07 -0.35 (-0.94%) Closing price 03:59 PM EasternExtended Trading$37.06 0.00 (-0.01%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
